In this issue:
Tislelizumab plus zanubrutinib in CLL patients with RT
Efficacy of mosunetuzumab plus polatuzumab vedotin
Comparison of I+V and FCR
MRD determining patient outcomes
Bendamustine toxicity in B-cell non-HL patients
Ibrutinib plus CAR T therapy
Durability and efficacy of axi-cel
Impact of BT
Inotuzumab ozogamicin and MRD
Dose-reduction immunochemotherapy in Burkitt lymphoma
Please login below to download this issue (PDF)